Trodelvy Now! Latest Update

Trodelvy Approved by NICE

METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.

Sex and Intimacy after a Breast Cancer Diagnosis

Sex and Intimacy

A diagnosis of cancer is a major life event. None of us is immune to the
potential of developing the disease. It doesn’t discriminate by age, gender,
sexual orientation or ethnicity. It can also develop in any part of the body. In
the case of breast cancer, one in seven women will be diagnosed with it
during their lifetime. Approximately 30% of those women will go on to develop secondary breast cancer.